Skip to main content

Market Overview

Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis

Share:
Eli Lilly Reveals More Phase 3 Data From Lebrikizumab Trial In Atopic Dermatitis

Eli Lilly And Co (NYSE: LLYoutlined more data for its IL-13 inhibitor in atopic dermatitis (AD) patients.

  • Lebrikizumab cleared up patients' skin at a statistically more significant rate than placebo.
  • The data come from a Phase 3 study looking at lebrikizumab combined with topical corticosteroids (TCS) in 211 adults and adolescents who suffer from moderate-to-severe AD. 
  • The primary endpoint was measured by a patient seeing their skin clear up by at least 75% from baseline, as assessed by the EASI-75 scale and an investigator assessment score.
  • Related: Lilly's Lebrikizumab Shows Clinical Benefit In Late-Stage Atopic Eczema Trials.
  • At 16 weeks, 41% of patients in the active arm achieved clear or almost clear skin through their IGA scores, compared to 22% taking placebo plus TCS. 
  • On the EASI-75 score, 70% of active arm patients hit the primary goal compared to 42% in the control arm.
  • Compared to placebo, patients treated with lebrikizumab plus TCS also achieved statistically significant improvements across key secondary endpoints, including skin clearance and itching, interference of itch on sleep, and quality of life measures. 
  • Price Action: LLY shares are down 0.45% at $310.28 during the market session on the last check Monday.
 

Related Articles (LLY)

View Comments and Join the Discussion!

Posted-In: atopic dermatitis Briefs Phase 3 TrialBiotech Large Cap News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com